Drug Trial Radar · NCT07767474
A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
343
Planned (sponsor's estimate)
Start
Aug 31, 2026
Primary completion
Oct 28, 2029
Study completion Jan 31, 2030
Sponsor
- Lead sponsor
- Antares Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study ATX-898-101 is a phase 1/2 open-label study evaluating the safety, tolerability, pharmacokinetic, and preliminary efficacy of ATX-898 as monotherapy and in combination with anti-neoplastic agents in selected solid tumors. This study consists of 2 parts. Part 1 evaluates ATX-898 as monotherapy and Part 2 evaluates ATX-898 in combination with anti-neoplastic agents of interest. Both parts will consists of a dose escalation portion and a dose expansion portion.
Conditions
- Advanced Solid Tumors
Interventions
ATX-898Drug
Doses defined per protocol
ATX-898Drug
RDE
ATX-898Drug
RDE
ATX-898Drug
RDE
ATX-898Drug
Doses defined per protocol
ATX-898, fulvestrant, ribociclibDrug
ATX-898 at RDE, Fulvestrant and abemaciclib: doses defined per protocol
ATX-898, fulvestrant, ribociclibDrug
ATX-898 at RDE, Fulvestrant and abemaciclib: doses defined per protocol
ATX-898, fulvestrant, ribociclibDrug
Doses defined per protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1a monotherapy dose escalation - Occurrence of Dose limiting toxicities (DLTs)Time frame: 12 months
- Part 1a monotherapy dose escalation - Maximally tolerated/tested dose (MTD)Time frame: 12 months
- Part 1a monotherapy dose escalation - Recommended dose for expansion (RDE)Time frame: 12 months
- Part 1a monotherapy dose escalation - Treatment emergent adverse events (TEAEs)Time frame: 12 months
- Part 1b monotherapy dose expansion - Objective Response Rate (ORR)Time frame: 24 months
- Part 2a combination dose escalation - Occurrence of Dose limiting toxicities (DLTs)Time frame: 18 months
- Part 2a combination dose escalation - Maximally tolerated/tested dose (MTD)Time frame: 18 months
- Part 2a combination dose escalation - Recommended dose for expansion (RDE)Time frame: 18 months
- Part 2a combination dose escalation - Treatment emergent adverse events (TEAEs)Time frame: 18 months
- Part 2b combination dose expansion - Objective Response Rate (ORR)Time frame: 36 months
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
START Dallas Fort Worth Cancer Center
Fort Worth, Texas · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
START San Antonio Cancer Center
San Antonio, Texas · Recruiting
START Mountain Region Cancer Center
West Valley City, Utah · Recruiting
NEXT Virginia Cancer Center- Merrifield Tech Center
Fairfax, Virginia · Recruiting
Linear Clinical Research
Perth, Western Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.